[Adjuvant chemotherapy in infiltrating bladder carcinoma. Long-term results].
The authors present the long-term of adjuvant chemotherapy using M-VEC scheme (Mtx 20 mg/mq; vinblastine 0.1 mg/kg; CDDP 40 mg/mq; epirubicin 30 mg/mq each 21 day for six cycles) effected in 28 patients (21 males and 7 women with average age of 67) undergone radical cystectomy for invasive bladder carcinoma p G2-3 T-4 N + M0. Total survival after 5 years was 28.6% while disease-free survival is 18.8%; in 71.3% there are been clinical progression and the mortality to 5 years was 62%.
Marino
G
G
Divisione di Urologia, Ospedale Mauriziano Umberto I, Torino.
Cocimano
V
V
Cevoli
R
R
Marten Perolino
R
R
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
D015251:Epirubicin; D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate
La chemioterapia adiuvante nel carcinoma vescicale infiltrante. Risultati a distanza.